China's National Medical Products Administration has approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Treatment depends on how deep the melanoma is and whether it has spread. This is called the stage of the cancer. Treatment also depends on your general health and where the melanoma is on your body.

An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) patients with a new all-tablet treatment showing impressive results.

The study enrolled 523 patients with untreated CLL, randomly assigning them to receive either MRD-driven ibrutinib-venetoclax therapy or standard FCR. After a median follow-up of 43.7 months ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic lymphocytic leukemia who received 1 prior line of therapy in the first article ...

The molecular mechanisms underlying resistance to therapy in Chronic lymphocytic leukemia (CLL) remain to be explored. Here, the authors perform multi-omics analysis in a mouse model of ibrutinib ...

Despite bendamustine's availability in Europe for 4 decades, the available clinical data shed little light on its role in the treatment of CLL. Adverse effects include myelosuppression and ...

Data are now accumulating on the feasibility of various treatment options even in unfit patients and there is an increased awareness that the chronological age by itself sometimes does not reflect ...

Panelists provide an overview of the current first-line treatment options for chronic lymphocytic leukemia (CLL), discussing the role of BTK inhibitors and venetoclax plus obinutuzumab (CLL14 ...